Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

C4 Therapeutics, Inc. (CCCC)

Biological Products, (no Disgnostic Substances)

https://www.c4therapeutics.com

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

490 ARSENAL WAY, SUITE 120
WATERTOWN, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/02/2020

Market Cap

405,625,545

Shares Outstanding

49,280,000

Weighted SO

49,281,046

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

STTK --.--%

ELYM --.--%

PRLD --.--%

GLUE --.--%

FHTX --.--%

CYT --.--%

RZLT --.--%

IPSC --.--%

EWTX --.--%

Beta

3.0720

Last Div

0.0000

Range

1.06-11.88

Chg

-0.0100

Avg Vol

1601266

Mkt Cap

405625545

Exch

NASDAQ

Country

US

Phone

617 231 0700

DCF Diff

7.2532

DCF

-1.4732

Div Yield

0.0000

P/S

13.8071

EV Multiple

-3.4207

P/FV

1.6293

Div Yield %

0.0000

P/E

-3.7318

PEG

-0.5360

Payout

0.0000

Current Ratio

5.0930

Quick Ratio

5.0930

Cash Ratio

1.3489

DSO

14.4991

DIO

0.0000

Op Cycle

14.4992

DPO

42.9550

CCC

-28.4559

Gross Margin

0.7359

Op Margin

-4.0471

Pretax Margin

-3.6282

Net Margin

-3.6717

Eff Tax Rate

0.0450

ROA

-0.2830

ROE

-0.4460

ROCE

-0.3637

NI/EBT

1.0120

EBT/EBIT

0.8965

EBIT/Rev

-4.0471

Debt Ratio

0.1795

D/E

0.2769

LT Debt/Cap

0.2030

Total Debt/Cap

0.2169

Int Coverage

46.1016

CF/Debt

-1.1373

Equity Multi

1.5425

Rec Turnover

25.1740

Pay Turnover

8.4973

Inv Turnover

999999.9999

FA Turnover

0.4362

Asset Turnover

0.0771

OCF/Share

-1.1308

FCF/Share

-1.1446

Cash/Share

3.8381

OCF/Sales

-2.6485

FCF/OCF

1.0123

CF Coverage

-1.1373

ST Coverage

-14.1649

CapEx Coverage

-81.5597

Div&CapEx Cov

-81.5597

P/BV

1.6293

P/B

1.6293

P/S

13.8071

P/E

-3.7318

P/FCF

-5.1500

P/OCF

-5.1735

P/CF

-5.1735

PEG

-0.5360

P/S

13.8071

EV Multiple

-3.4207

P/FV

1.6293

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 08, 17:30 C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader GlobeNewswire Inc. Sep 08, 22:05 C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 Zacks Investment Research Jan 01, 09:55 Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High? MarketWatch Dec 13, 08:36 Throw away those target-date funds, and don't hold bonds at all, says this daring new research Benzinga Dec 13, 07:44 D.R. Horton To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday Benzinga Dec 12, 14:23 Crude Oil Down 4%; Aditxt Shares Spike Higher Benzinga Dec 12, 11:58 Dow Jumps Over 100 Points; Oracle Posts Mixed Q2 Results

Revenue Product Segmentation